US 12,042,294, filed under application 17/989,429 and issued on July 16, 2024, introduces a system and method developed by Dr. Wesley W.O. Krueger to measure ocular parameters and determine neurologic health status. This innovation utilizes advanced eye-tracking technology, likely integrated into head-worn or wearable devices, to monitor eye movements, pupil responses, and other ocular metrics, providing real-time assessments of neurologic conditions (e.g., concussions, stroke, neurodegenerative diseases). Validated through NIH-supported research, this platform-agnostic technology leverages Dr. Krueger’s neurotology expertise to offer a precise and accessible tool for neurologic health monitoring.
Potential Applications
Medical Diagnostics: Detects and monitors neurologic conditions such as TBIs, Parkinson’s, and multiple sclerosis, aiding early intervention.
Occupational Safety: Assesses neurologic health for workers in high-stakes roles like trucking, aviation, and manufacturing, reducing $74 billion in annual accident costs (NHTSA, 2024).
Defense Health Monitoring: Evaluates soldier neurologic status and TBI recovery in special operations or combat zones, minimizing $1B+ mission risks.
Rehabilitation Tracking: Guides recovery from neurologic injuries in rehab facilities, improving return-to-activity decisions.
Pharmaceutical Research: Measures ocular responses to evaluate drug efficacy for CNS disorders, providing objective clinical trial data.
Potential Users
Healthcare Providers: Neurologists, neurosurgeons, and rehab specialists diagnosing and monitoring neurologic health.
Occupational Workers: 3.5 million U.S. truck drivers, air traffic controllers, and 10M+ safety-sensitive workers globally (BLS, 2024).
Military Personnel: Special ops, infantry, and pilots (1.3M active-duty U.S. forces) requiring neurologic assessments in the field.
Rehab Patients: Individuals recovering from TBIs or neurologic conditions (5–60 million annual non-sport TBIs globally).
Pharmaceutical Researchers: Clinical trial managers assessing CNS-affecting therapies.
Potential Buyers or Licensees
Medical Device Companies: GE Healthcare and Neurosoft ($40M–$60M licensing) could integrate into diagnostic and monitoring devices, aligning with $50M+ medical tech investments.
Defense Contractors: BAE Systems and Northrop Grumman ($50M–$70M licensing) may adopt for soldier health systems, leveraging the DoD’s $11.7B R&D budget (2025).
Big Tech: Samsung (R&D $15B+) and Apple (R&D $26B) could license for wearable health features ($20M–$50M), targeting the $635.82B wearable market (2034).
Rehab Equipment Providers: Dynatronics and Enraf-Nonius ($25M–$40M licensing) could enhance therapy tools.
Pharma Giants: Roche and Merck ($30M–$50M licensing) could use for drug efficacy trials, tapping the $180.6B CNS market (2030).
Market Appeal and Valuation
This patent targets a $20B–$30B global market for neurologic health, occupational safety, and pharmaceutical research, with a per-patent value of $25M–$80M (average $52.5M), reflecting its specialized neurologic focus. Licensing fees could range from $20M–$50M per deal, with royalties (1–5%) adding $5M–$15M annually. Within Dr. Krueger’s 20-patent portfolio, valued at US$750M–$1.68B, this patent strengthens the medical and defense segments, with an upside to US$2.5B–$3B, enhanced by its synergy with ocular performance patents.
Investment Rationale
S 12,042,294 offers a compelling appeal by disrupting traditional neurologic assessments (e.g., MRI, subjective exams) with a rapid, objective, and portable solution. Its integration into wearables and health systems generates substantial downstream revenue, aligning with big tech’s health tech push, DoD safety priorities, and pharmaceutical needs. Potential buyers or licensees can leverage its validated efficacy and versatility to lead in neurologic health, safety, and performance innovation.